Why the study?
Does VEGFR inhibition with SU5416 combined with chronic hypoxia induce severe pulmonary arterial hypertension pathology in mice compared to hypoxia alone?
Population
Murine model
Comparison
Inhibition of vascular endothelial growth factor… vs Hypoxia alone
Design
Preclinical
Follow-up
3 weeks
Key result
Inhibition of VEGFR with SU5416 combined with 3 weeks of chronic hypoxia profoundly exacerbated PAH-like pathology in mice compared with hypoxia alone (> 45 mm Hg right ventricular pressure).
Authors
Loading...
No immediate clinical implications; extends murine models available for severe PAH research.
Does VEGFR inhibition with SU5416 combined with chronic hypoxia induce severe pulmonary arterial hypertension pathology in mice compared to hypoxia alone?
The combination of SU5416 and chronic hypoxia establishes a novel murine model that closely mimics severe human pulmonary arterial hypertension.
Ciuclan et al. (2011) studied Severe pulmonary arterial hypertension. SU5416 combined with chronic hypoxia vs. Hypoxia alone was evaluated on PAH pathology development (hemodynamics, cardiac function, histological assessment). Inhibition of VEGFR with SU5416 combined with 3 weeks of chronic hypoxia profoundly exacerbated PAH-like pathology in mice compared with hypoxia alone (> 45 mm Hg right ventricular pressure).